Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Abnormal ALT -68% Improvement Relative Risk Chew et al. Remdesivir for COVID-19 EARLY TREATMENT Is early treatment with remdesivir beneficial for COVID-19? Retrospective 163 patients in Singapore (January - April 2020) Higher progression with remdesivir (not stat. sig., p=0.4) Chew et al., Pathogens, doi:10.3390/pathogens12030473 Favors remdesivir Favors control
Clinical Predictors for Abnormal ALT in Patients Infected with COVID-19—A Retrospective Single Centre Study
Chew et al., Pathogens, doi:10.3390/pathogens12030473
Chew et al., Clinical Predictors for Abnormal ALT in Patients Infected with COVID-19—A Retrospective Single Centre Study, Pathogens, doi:10.3390/pathogens12030473
Mar 2023   Source   PDF  
  All Studies   Meta
Retrospective 163 COVID-19 patients in Singapore, showing increased risk of liver injury (abnormal ALT) with acetaminophen in a dose-dependent manner, and with remdesivir, without statistical significance in both cases.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
This study includes remdesivir and acetaminophen.
abnormal ALT, 68.0% higher, OR 1.68, p = 0.40, treatment 12, control 151, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chew et al., 16 Mar 2023, retrospective, Singapore, peer-reviewed, median age 56.0, 7 authors, study period 23 January, 2020 - 15 April, 2020.
Contact: (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Clinical Predictors for Abnormal ALT in Patients Infected with COVID-19—A Retrospective Single Centre Study
Wei Da Chew, Jonathan Kuang, Huiyu Lin, Li Wei Ang, Wei Lyn Yang, David C Lye, Barnaby E Young
Pathogens, doi:10.3390/pathogens12030473
Objective: Abnormal liver tests have been associated with worse clinical outcomes in patients infected with COVID-19. This retrospective observational study from Singapore aims to elucidate simple clinical predictors of abnormal alanine aminotransferase (ALT) in COVID-19 infections. Design: 717 patients hospitalised with COVID-19 at the National Centre for Infectious Diseases (NCID), Singapore, from 23 January-15 April 2020 were screened, of which 163 patients with baseline normal alanine transferase (ALT) and at least two subsequent ALTs performed were included in the final analysis. Information on baseline demographics, clinical characteristics and biochemical laboratory tests were collected. Results: 30.7% of patients developed abnormal ALT. They were more likely to be older (60 vs. 55, p = 0.022) and have comorbidities of hyperlipidaemia and hypertension. The multivariate logistic regression showed that R-factor ≥1 on admission (adjusted odds ratio (aOR) 3.13, 95% Confidence Interval (CI) 1.41-6.95) and hypoxia (aOR 3.54, 95% CI 1.29-9.69) were independent risk factors for developing abnormal ALT. The patients who developed abnormal ALT also ran a more severe course of illness with a greater proportion needing supplementary oxygen (58% vs. 18.6%, p < 0.0005), admission to the Intensive Care Unit (ICU)/High Dependency Unit (HDU) (32% vs. 11.5%, p = 0.003) and intubation (20% vs. 2.7%, p < 0.0005). There was no difference in death rate between the two groups. Conclusions: Liver injury is associated with poor clinical outcomes in patients with COVID-19. R-factor ≥1 on admission and hypoxia are independent simple clinical predictors for developing abnormal ALT in COVID-19.
Conflicts of Interest: Barnaby E Young has received honoraria from Sanofi and Roche outside of the submitted work. Wei Da Chew, Jonathan Kuang, Huiyu Lin, Li Wei Ang, Wei Lyn Yang and David C Lye declare that they have no conflicts of interest.
Akdogan, Guzel, Tosun, Akpinar, Diagnostic and early prognostic value of serum CRP and LDH levels in patients with possible COVID-19 at the first admission, J. Infect. Dev. Ctries, doi:10.3855/jidc.14072
Aroniadis, Dimaio, Dixon, Elmunzer, Kolb et al., Current Knowledge and Research Priorities in the Digestive Manifestations of COVID-19, Clin. Gastroenterol. Hepatol, doi:10.1016/j.cgh.2020.04.039
Bertolini, Van De, Peppel, Bodewes, Moshage et al., Abnormal liver function tests in COVID-19 patients: Relevance and potential pathogenesis, Hepatology, doi:10.1002/hep.31480
Cai, Huang, Yu, Zhu, Xia et al., COVID-19: Abnormal liver function tests, J. Hepatol, doi:10.1016/j.jhep.2020.04.006
Dufour, Marjot, Becchetti, Tilg, COVID-19 and liver disease, Gut, doi:10.1136/gutjnl-2021-326792
Fan, Chen, Li, Cheng, Yang et al., Clinical Features of COVID-19-Related Liver Functional Abnormality, Clin. Gastroenterol. Hepatol, doi:10.1016/j.cgh.2020.04.002
Ferm, Fisher, Pakala, Tong, Shah et al., Analysis of Gastrointestinal and Hepatic Manifestations of SARS-CoV-2 Infection in 892 Patients in Queens, Clin. Gastroenterol. Hepatol, doi:10.1016/j.cgh.2020.05.049
Guan, Ni, Hu, Liang, Qu et al., Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Havers, Pham, Taylor, Whitaker, Patel et al., COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to, JAMA Intern. Med, doi:10.1001/jamainternmed.2022.4299
Henry, Aggarwal, Wong, Benoit, Vikse et al., Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis, Am. J. Emerg. Med, doi:10.1016/j.ajem.2020.05.073
Hundt, Deng, Ciarleglio, Nathanson, Lim, Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network, Hepatology, doi:10.1002/hep.31487
Kumar-M, Mishra, Jha, Shukla, Choudhury et al., COVID-19 and the liver: A comprehensive systematic review and meta-analysis, Hepatol. Int, doi:10.1007/s12072-020-10071-9
Kwo, Cohen, Lim, ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries, Am. J. Gastroenterol, doi:10.1038/ajg.2016.517
Lagana, Kudose, Iuga, Lee, Fazlollahi et al., Hepatic pathology in patients dying of COVID-19: A series of 40 cases including clinical, histologic, and virologic data, Mod. Pathol, doi:10.1038/s41379-020-00649-x
Lei, Liu, Zhou, Qin, Zhang et al., Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China, Hepatology, doi:10.1002/hep.31301
Mathieu, Ritchie, Ortiz-Ospina, Roser, Hasell et al., A global database of COVID-19 vaccinations, Nat. Hum. Behav, doi:10.1038/s41562-021-01122-8
Mcgrowder, Miller, Cross, Anderson-Jackson, Bryan et al., Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis, Diseases, doi:10.3390/diseases9030050
Piano, Dalbeni, Vettore, Benfaremo, Mattioli et al., Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19, Liver Int
Portincasa, Krawczyk, Machill, Lammert, Di Ciaula, Hepatic consequences of COVID-19 infection. Lapping or biting?, Eur. J. Intern. Med, doi:10.1016/j.ejim.2020.05.035
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA, doi:10.1001/jama.2020.6775
Sarin, Kumar, Lau, Abbas, Chan et al., Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update, Hepatol. Int, doi:10.1007/s12072-015-9675-4
Sun, Aghemo, Forner, Valenti, COVID-19 and liver disease, Liver Int, doi:10.1111/liv.14470
Torge, Bernardi, Arcangeli, Bianchi, Histopathological Features of SARS-CoV-2 in Extrapulmonary Organ Infection: A Systematic Review of Literature, Pathogens, doi:10.3390/pathogens11080867
Vespa, Pugliese, Piovani, Capogreco, Danese et al., Liver tests abnormalities in COVID-19: Trick or treat?, J. Hepatol, doi:10.1016/j.jhep.2020.05.033
Wang, Gao, Li, Xu, Zhou et al., Early changes in laboratory tests predict liver function damage in patients with moderate coronavirus disease 2019: A retrospective multicenter study, BMC Gastroenterol, doi:10.1186/s12876-022-02188-y
Wang, Yan, Qi, Wu, Zhu et al., Clinical characteristics and risk factors of liver injury in COVID-19: A retrospective cohort study from Wuhan, China, Hepatol. Int, doi:10.1007/s12072-020-10075-5
Wu, Mcgoogan, Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Xu, Shi, Wang, Zhang, Huang et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med, doi:10.1016/S2213-2600(20)30076-X
Yip, Lui, Wong, Chow, Ho et al., Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19, Gut
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop